Real-World Evidence on Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis

This study evaluated the real-world efficacy and safety of Janus Kinase inhibitors (JAKi) in treating moderate to severe active Ulcerative Colitis (UC) in 68 patients, with an additional 6 patients assessed for secondary outcomes. The results showed that 76% of patients achieved clinical remission, and 67% achieved biochemical remission. However, 30% of patients discontinued treatment due to lack of efficacy or adverse events (AEs), with 53% reporting AEs such as hypercholesteremia and flu-like symptoms. Despite these AEs, 87% of patients continued treatment. The study concluded that JAKi are effective in inducing remission in UC patients and have an acceptable safety profile, consistent with clinical data.